{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:19:14Z","timestamp":1764605954804,"version":"3.46.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.advms.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:58:41Z","timestamp":1759996721000},"page":"392-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The transition from intravenous to subcutaneous infliximab in a cohort of patients with inflammatory bowel disease: results of the INESTIMABLE retrospective observational study"],"prefix":"10.1016","volume":"70","author":[{"given":"Alessia","family":"Todeschini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Geccherle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Signoretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Colaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Mellone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-3692","authenticated-orcid":false,"given":"Nicoletta","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-539X","authenticated-orcid":false,"given":"Massimo","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0995-8683","authenticated-orcid":false,"given":"Giuliano","family":"Barugola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Variola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.advms.2025.10.001_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.advms.2025.10.001_bib2","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.advms.2025.10.001_bib3","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.advms.2025.10.001_bib4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Torres","year":"2022","journal-title":"J Crohn's Colitis"},{"issue":"5","key":"10.1016\/j.advms.2025.10.001_bib5","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2018.06.043","article-title":"Treatments for Crohn's disease-associated bowel damage: a systematic review","volume":"17","author":"Pariente","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2025.10.001_bib6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrgastro.2009.220","article-title":"The potential for disease modification in Crohn's disease","volume":"7","author":"Van Assche","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"year":"2023","series-title":"ZYMFENTRA (Infliximab-dyyb) injection, for subcutaneous use [prescribing information]","key":"10.1016\/j.advms.2025.10.001_bib8"},{"issue":"11","key":"10.1016\/j.advms.2025.10.001_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166443","article-title":"Accelerated infliximab infusion: safety, factors predicting adverse events, patients' satisfaction and cost analysis. A cohort study in IBD patients","volume":"11","author":"Mazzuoli","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2025.10.001_bib10","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.advms.2025.10.001_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.dld.2023.12.013","article-title":"Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: post hoc longitudinal analysis of a randomized trial","volume":"56","author":"Schreiber","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1016\/j.advms.2025.10.001_bib12","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.advms.2025.10.001_bib13","first-page":"118","article-title":"Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results","volume":"114","author":"Arg\u00fcelles-Arias","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.advms.2025.10.001_bib14","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CTP13]: a multicentre cohort study","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.advms.2025.10.001_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous Infliximab maintenance therapy compared with intravenous Infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.advms.2025.10.001_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","article-title":"Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for inflammatory bowel disease: two randomized phase 3 trials (LIBERTY)","volume":"167","author":"Hanauer","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.advms.2025.10.001_bib17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5009\/gnl230291","article-title":"Effectiveness of switching to subcutaneous Infliximab in ulcerative colitis patients experiencing intravenous Infliximab failure","volume":"18","author":"Bae","year":"2024","journal-title":"Gut Liver"},{"issue":"9","key":"10.1016\/j.advms.2025.10.001_bib18","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. real clinical practice multicentre study","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.advms.2025.10.001_bib19","unstructured":"European Medicines Agency. Remsima [Internet]. Amsterdam: European Medicines Agency; [cited 2025 Sep 25]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/remsima."},{"issue":"8167","key":"10.1016\/j.advms.2025.10.001_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.advms.2025.10.001_bib21","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"Lewis","year":"2008","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.advms.2025.10.001_bib22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.dld.2024.09.015","article-title":"Persistence of subcutaneous versus intravenous infliximab in a real-life cohort: a propensity-score matched comparative analysis","volume":"57","author":"Bothorel","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"7","key":"10.1016\/j.advms.2025.10.001_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081787","article-title":"Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial","volume":"14","author":"Little","year":"2024","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.advms.2025.10.001_bib24","first-page":"549","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"issue":"24","key":"10.1016\/j.advms.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.3390\/jcm11247296","article-title":"Inflammatory bowel disease patients' acceptance for switching from intravenous Infliximab or vedolizumab to subcutaneous formulation: the nancy experience","volume":"11","author":"Remy","year":"2022","journal-title":"J Clin Med"},{"issue":"134","key":"10.1016\/j.advms.2025.10.001_bib26","first-page":"1654","article-title":"Patients' assessment of adalimumab self-injection for Crohn's disease: a multicenter questionnaire survey (the PEARL Survey)","volume":"61","author":"Hirai","year":"2014","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"10.1016\/j.advms.2025.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/eci.14283","article-title":"An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: the TIME study","volume":"54","author":"D'Amico","year":"2024","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.advms.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae127","article-title":"Subcutaneous Infliximab cutoff points in patients with inflammatory bowel disease: data from the ENEIDA registry","volume":"19","author":"Iborra","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.advms.2025.10.001_bib29","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1007\/s10620-024-08631-2","article-title":"Transition to subcutaneous Infliximab vs vedolizumab in inflammatory bowel disease: a prospective multicenter study","author":"Principi","year":"2024","journal-title":"Dig Dis Sci"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112625000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112625000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:16:30Z","timestamp":1764605790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112625000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1896112625000422"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2025.10.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"type":"print","value":"1896-1126"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The transition from intravenous to subcutaneous infliximab in a cohort of patients with inflammatory bowel disease: results of the INESTIMABLE retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Medical University of Bialystok. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}